Cytiva Cell and Gene Webinars and Podcasts

1. March Cytiva Webinar 3/11/2026
2. Five Practical Considerations To Move From Concept To Clinic 12/17/2025

   Learn more about five key factors for advancing targeted in vivo LNP programs, from formulation and targeting strategies to bioanalytical readiness and scalability.

3. Hear From The Experts: LNPs Driving The Future Of Cell Therapy 12/12/2025

   Explore how lipid nanoparticles are driving breakthroughs in cell therapy, from mRNA-based immune cell engineering to genome editing for CAR T cells and HSPCs from leading experts.

4. Streamlining pDNA: Capacity, Complexity, And Cutting-Edge Solutions 11/20/2025

   Learn how flexible facility design and process innovation are accelerating pDNA manufacturing, as well as key strategies to avoid scale-up pitfalls and meet growing therapeutic demand.

5. Are You Keeping Pace With Oligo Synthesis Optimization? 11/18/2025

   The rapidly expanding oligo market demands optimized RNA synthesis. Examine key innovations and workflow insights to maximize resources and control long-term manufacturing costs.

6. CRISPR Meets LNPs: A New Era In Cell And Gene Therapies 7/8/2025

   Explore how lipid nanoparticles are revolutionizing non-viral gene editing with scalable, efficient delivery for both ex vivo and in vivo applications, which features new CRISPR-LNP data in T cells.

7. Simplify CAR-T Cell Manufacturing With LNP-Mediated Delivery 6/3/2025

   Streamline CAR-T cell manufacturing with lipid nanoparticles delivering base editors to create fratricide-resistant, CD45-edited CAR45 T cells, which enables scalable, precise, and potent therapies for blood cancers.

8. Insights And Strategies For GMP Manufacturing Of RNA-Lipid Nanoparticles 4/25/2024

   The emergence of RNA-encapsulated-lipid nanoparticles has introduced a seismic shift in biopharma innovation. But how will the industry adapt to diversifying applications and scales going forward?

9. Translation Of RNA Nanomedicines From Design To Clinical 4/14/2022

   mRNA therapeutics are applicable to cancer immunotherapies, infectious diseases, and other indications that require protein replacement therapy or antibodies.

10. mRNA LNP Scale Up For GMP Vaccine Production 4/14/2022

    Explore an overview of the development and scale-up activities needed to develop high quality lipid nanoparticles and progress this saRNA vaccine to the clinic.